Oral oncology最新文献

{"title":"Efficacy of boron neutron capture therapy (BNCT) for patients with oral cancer","authors":"Jun Miyaguchi ,&nbsp;Kiyoto Shiga ,&nbsp;Katsunori Katagiri ,&nbsp;Daisuke Saito ,&nbsp;Kodai Tsuchida ,&nbsp;Takahiro Kusaka ,&nbsp;Yu Ohashi ,&nbsp;Iori Kusaka ,&nbsp;Yoshihiro Takai","doi":"10.1016/j.oraloncology.2025.107228","DOIUrl":"10.1016/j.oraloncology.2025.107228","url":null,"abstract":"<div><h3>Background</h3><div>Although BNCT is a novel therapy for head and neck cancers, its efficacy in patients with oral cancer remains unclear.</div></div><div><h3>Patients and methods</h3><div>Nine patients with oral cancer underwent BNCT at Southern Tohoku BNCT Research Center. We reviewed the charts and diagnostic images of these patients and analyzed their responses and adverse events associated with the therapy.</div></div><div><h3>Results</h3><div>All patients underwent surgery and/or radiotherapy as initial treatment for head and neck cancer. No patients had distant metastases at the time of BNCT. The median observation period was 16 months. Grade 3 and 4 adverse events were observed in six patients who recovered within one month. Treatment responses were complete in seven patients and partial in two. Overall survival, disease-specific survival, and local control rates of the patients at one year were 76.2, 76.2, and 87.5 %, respectively.</div></div><div><h3>Conclusion</h3><div>Our study suggested that BNCT is a relatively safe and effective treatment for patients with recurrent and/or advanced oral cancer.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"163 ","pages":"Article 107228"},"PeriodicalIF":4.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143521251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of a comprehensive set of normal tissue complication probability models for patients with head and neck cancer in an international cohort","authors":"Suzanne P.M. de Vette ,&nbsp;Maria I. van Rijn-Dekker ,&nbsp;Lisa Van den Bosch ,&nbsp;Kylie Keijzer ,&nbsp;Hendrike Neh ,&nbsp;Hung Chu ,&nbsp;Yan Li ,&nbsp;Mark L. Frederiks ,&nbsp;Hans Paul van der Laan ,&nbsp;Jolien Heukelom ,&nbsp;Peter van Luijk ,&nbsp;Arjen van der Schaaf ,&nbsp;Roel J.H.M. Steenbakkers ,&nbsp;Nanna M. Sijtsema ,&nbsp;Katherine A. Hutcheson ,&nbsp;Clifton D. Fuller ,&nbsp;Johannes A. Langendijk ,&nbsp;Amy C. Moreno ,&nbsp;Lisanne V. van Dijk","doi":"10.1016/j.oraloncology.2025.107224","DOIUrl":"10.1016/j.oraloncology.2025.107224","url":null,"abstract":"<div><h3>Background/purpose</h3><div>Normal tissue complication probability (NTCP) models can be used to guide radiation therapy (RT) decisions by estimating side-effect risks pretreatment to minimize (late) side-effects. Recently, a comprehensive individual toxicity risk (CITOR) profile of NTCP models addressing common side-effects in head and neck cancer (HNC) patients was developed. This study investigates the generalizability of these models in an international setting, with different treatment approaches and side-effect assessments, promoting their integration into more widespread clinical practice.</div></div><div><h3>Materials/methods</h3><div>From a prospective registry study, 407 HNC patients were included who were treated with definitive RT with or without systemic therapy between 2015 and 2022. NTCP models predicting dysphagia, aspiration, xerostomia, sticky saliva, taste loss, speech problems, oral pain, and fatigue at 6 and 12 months after RT were evaluated. All side-effects were patient-rated using the MDASI-HN, except dysphagia which was reported by clinicians using the PSS-HN diet normalcy score. Model performance was appraised by discrimination (area under the curve [AUC]) and calibration.</div></div><div><h3>Results</h3><div>CITOR models showed moderate-to-high performance in this cohort (mean AUC = 0.67[range = 0.55–0.80], moderate-to-good calibration). NTCP models for dysphagia, xerostomia, sticky saliva, and fatigue were the top performing models. Models for aspiration, taste loss and speech problems performed moderately well, which was partly explained by lower incidences.</div></div><div><h3>Conclusion</h3><div>Despite differences between the CITOR development and this evaluation cohort, including use of different side-effect scoring systems, most models exhibited moderate-to-high performance. This demonstrated that the dose–effect relations were generalizable. Therefore, this study supports further integration of these NTCP models in clinical practice.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"163 ","pages":"Article 107224"},"PeriodicalIF":4.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143526558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microscopic findings in oral squamous cell carcinoma with cystic spaces and clear cells mimicking mucoepidermoid carcinoma: A detailed case report","authors":"Moisés Willian Aparecido Gonçalves ,&nbsp;Iara Vieira Ferreira ,&nbsp;Maria Clara Falcão Ribeiro-de-Assis ,&nbsp;Carlos Takahiro Chone ,&nbsp;Natália Vital Gonçalves ,&nbsp;Albina Altemani ,&nbsp;Fernanda Viviane Mariano","doi":"10.1016/j.oraloncology.2025.107230","DOIUrl":"10.1016/j.oraloncology.2025.107230","url":null,"abstract":"<div><div>A 62-year-old male was referred for management of oral squamous cell carcinoma (OSCC), previously diagnosed in another service. The patient complained of persistent oral discomfort for 10 months, reported being a social drinker, and denied smoking. Intraoral examination revealed a vegetating, hardened lesion, measuring 3.0 cm, in transition between the retromolar trigone, soft palate, and buccal mucosa. Microscopic examination of the incisional biopsy performed previously revealed malignant epithelial cells proliferate and invade the surrounding stroma as islands and cords of epithelial cells, with the presence of cystic spaces and clear cells, resembling mucoepidermoid carcinoma (MEC). The histological findings led to a diagnosis of MEC or OSCC. Based on the correlation between the morphological, immunohistochemical, and histochemical findings, the diagnosis of OSCC with cystic spaces and clear cells was supported. The patient was referred for further therapeutic intervention. Recognizing the histological variants of OSCC is important, due to the similarity with other neoplasms.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"163 ","pages":"Article 107230"},"PeriodicalIF":4.0,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143512099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the editor, “Mitoxantrone hydrochloride liposome injection for the treatment of Recurrent/Metastatic head and neck squamous cell carcinoma: A multicenter, open-label, single-arm, phase 1b study.”","authors":"Gnanaprakash Jeyaraj","doi":"10.1016/j.oraloncology.2025.107231","DOIUrl":"10.1016/j.oraloncology.2025.107231","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"163 ","pages":"Article 107231"},"PeriodicalIF":4.0,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143487365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant chemoimmunotherapy brings superior quality of life of patients with locally advanced oral or oropharyngeal cancer: A propensity score-matched analysis","authors":"Wen-Jie Wu ,&nbsp;Pu-Gen An ,&nbsp;Qian Liu ,&nbsp;Zi-Qi Zhang ,&nbsp;Xiao Hu ,&nbsp;Jie Yao ,&nbsp;Jie Zhang","doi":"10.1016/j.oraloncology.2025.107218","DOIUrl":"10.1016/j.oraloncology.2025.107218","url":null,"abstract":"<div><h3>Background</h3><div>The outcomes and quality of life of patients with locally advanced oral or oropharyngeal squamous cell carcinoma (LAOOPSCC) following upfront surgery (US) are suboptimal. The optimal neoadjuvant therapy involving programmed death-1 inhibitors still remains unknown. We aimed to investigate the antitumor efficacy and quality-of-life benefits of neoadjuvant chemoimmunotherapy (NACI) and compare them with those of US for LAOOPSCC.</div></div><div><h3>Methods</h3><div>A total of 570 patients with OOPSCC who underwent surgical treatment between January 2021 and January 2023 were initially reviewed and we obtained 51 unbiased patients in each of the NACI and US groups through propensity score matching based on age, sex, clinical T and N stage. The antitumor efficacy in patients in the NACI group was evaluated with the pathological response. The postoperative quality of life, as assessed with the EORTC Quality of Life Questionnaire Head and Neck 35, as well as disease-free survival and overall survival, were compared between the groups.</div></div><div><h3>Results</h3><div>In the NACI group, the major pathological response rate was 58.8 % (30/51), and the objective response rate was 66.7 % (34/51). In NACI group, In the NACI group, patients experienced a shorter operative time (p = 0.001) and a reduced length of hospitalization post-surgery (p = 0.041), along with less intraoperative blood loss (p &lt; 0.001) and fewer free flap reconstructions (p &lt; 0.001). Compared with the patients in the US group, those in the NACI group had significantly better postoperative quality of life, including the sensory function (12.7 vs. 23.0, p = 0.021), speech problems (17.3 vs. 35.1, p &lt; 0.001), social eating (20.8 vs. 31.0, p = 0.020), social contact (19.8 vs. 36.5, p &lt; 0.001) and feeling ill (41.2 vs. 51.6, p = 0.021). There was no significant statistical difference in OS (p = 0.825) and DFS (p = 0.473) between the two groups.</div></div><div><h3>Conclusion</h3><div>The findings demonstrate the safety and feasibility of NACI and the de-escalation surgery after NACI is worth promoting to improve patient postoperative quality of life.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"162 ","pages":"Article 107218"},"PeriodicalIF":4.0,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143488715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Squamous cell carcinoma in the posterior larynx: A rare localization of supraglottic T1 laryngeal cancer. Case report","authors":"M. Wiczuk-Wiczewska ,&nbsp;J. Bernaciak ,&nbsp;P. Nogal ,&nbsp;A. Bugaj ,&nbsp;J. Jackowska","doi":"10.1016/j.oraloncology.2025.107227","DOIUrl":"10.1016/j.oraloncology.2025.107227","url":null,"abstract":"<div><div>Laryngeal squamous cell carcinoma (SCC) is a common malignancy of the head and neck, typically presenting in older patients with a history of smoking or alcohol use. However, its progression can be unpredictable, with cases of long-term dormancy followed by rapid progression. We report a case of a 71-year-old male with an 18-year history of otolaryngological treatment who presented with a newly diagnosed laryngeal SCC after multiple benign findings in previous laryngoscopies. The patient underwent CO₂ laser excision of the tumour, and subsequent histopathological examination confirmed the presence of SCC. Follow-up imaging and microlaryngoscopy revealed no residual tumour or metastasis. The patient remains under surveillance.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"163 ","pages":"Article 107227"},"PeriodicalIF":4.0,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143487366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary on, “Oncologic significance of the lateral margin in buccal cancer.”","authors":"Gnanaprakash Jeyaraj","doi":"10.1016/j.oraloncology.2025.107232","DOIUrl":"10.1016/j.oraloncology.2025.107232","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"163 ","pages":"Article 107232"},"PeriodicalIF":4.0,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143487367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comments on “Achieving negative superficial resection margins with NBI and white light in carcinoma oral cavity: Could it be a norm?”","authors":"F. Boscolo Nata,&nbsp;G. Tirelli","doi":"10.1016/j.oraloncology.2025.107226","DOIUrl":"10.1016/j.oraloncology.2025.107226","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"163 ","pages":"Article 107226"},"PeriodicalIF":4.0,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of patient derived xenograft model in personalized drug screening for chondrosarcoma of head and neck: A preclinical study","authors":"Yufei Hua ,&nbsp;Zhiyong Guo ,&nbsp;Ying Wang ,&nbsp;Chunjie Li ,&nbsp;Bing Yan","doi":"10.1016/j.oraloncology.2025.107222","DOIUrl":"10.1016/j.oraloncology.2025.107222","url":null,"abstract":"<div><h3>Objectives</h3><div>The effect of radiotherapy and chemotherapy on head and neck chondrosarcoma (HNCS) has not been unanimously determined because of the rarity of HNCS. Patient-Derived Xenograft (PDX) model is considered to be a good preclinical model for new drug development and personalized drug screening. We performed this study to investigate the preclinical application and value of PDX model in drug screening for HNCS.</div></div><div><h3>Materials and methods</h3><div>Tumor tissues of a patient with HNCS who underwent surgical treatment in the Department of Head and Neck Oncology of our hospital were collected. The PDX model was established in NCG mice and successfully passed to the P3 generation in nude mice. After the tumor grew to a certain size, three drugs targeting different molecules (Nilotinib, Regorafenib, Rapamycin) were given respectively. The treatment efficiency and safety were observed.</div></div><div><h3>Results</h3><div>NCG mouse is a kind of mouse that can successfully establish the PDX model of HNCS, and the PDX model can be stably passed in nude mice. The PDX tumor show similar histopathological characteristics to the parent tumors. After stable passaging, the mesenchymal cells were reduced and the tumor cells were increased in PDX tumor, making it easier to extract primary tumor cells. In the P3 PDX tumor, oral administration of nilotinib and regorafenib or intraperitoneal injection of rapamycin could significantly reduce the tumor size.</div></div><div><h3>Conclusion</h3><div>For rare tumors such as HNCS, PDX model is a good preclinical model for personalized drug screening and has good clinical application value.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"162 ","pages":"Article 107222"},"PeriodicalIF":4.0,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143478883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Model-free parameters derived from intravoxel inherent motion combined with tumor aggressiveness indicators in predicting 5-year treatment outcome in NPC","authors":"Fan Yang ,&nbsp;Wenjing Peng ,&nbsp;Haoran Wei ,&nbsp;Xiaolu Li ,&nbsp;Xiaoduo Yu ,&nbsp;Lin Li ,&nbsp;Yanfeng Zhao ,&nbsp;Lizhi Xie ,&nbsp;Meng Lin ,&nbsp;Hongmei Zhang","doi":"10.1016/j.oraloncology.2025.107187","DOIUrl":"10.1016/j.oraloncology.2025.107187","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the value of model-free parameters (virtual magnetic resonance elastography [vMRE] and signature index [S-index]) and tumor aggressiveness indicators (contralateral pharyngeal recess invasion [CPRI] and tumor growth type [TGT]) in forecasting 5-year treatment outcomes in nasopharyngeal carcinoma (NPC).</div></div><div><h3>Materials and Methods</h3><div>A total of 106 patients were included in this study. Only two b-values were employed to calculate vMRE and S-index. Univariate and multivariate Cox analyses were conducted with clinical factors as confounding variables. Multivariate logistic analysis was used to construct multiple models. The additional value of CPRI and TGT was evaluated through net reclassification improvement index (NRI) and integrated discrimination improvement (IDI). Model performance and robustness were evaluated.</div></div><div><h3>Results</h3><div>The predictive performance of vMRE and S-index (area under the curve [AUC]: 0.620 ∼ 0.639) was comparable to that of model-based parameters (AUC: 0.570 ∼ 0.658, all P ≥ 0.366). CPRI and TGT independently predicted progression-free survival (PFS) and overall survival (OS). Combined models significantly outperformed than the TNM stage model (all P ≤ 0.002) and vMRE-based or S-index-based model (all NRI ≥ 0.105 and IDI ≥ 0.085) in terms of 5-year OS (AUC: 0.840 ∼ 0.843) and 5-year PFS (AUC: 0.786 ∼ 0.793). The combined model demonstrated robust performance through Hosmer-Lemeshow test, cross-validation (iteration = 1000), 7:3 validation (chronologically or randomly), and post-hoc subgroup analysis.</div></div><div><h3>Conclusion</h3><div>The advent of vMRE and S-index has streamlined the clinical applications without compromising the value of IVIM technique. Incorporating CPRI and TGT has further enhanced the predictive performance.</div></div><div><h3>Clinical relevance statement</h3><div>Only two b-values are needed to calculate vMRE and S-index, which, along with CPRI and TGT, are pivotal in forecasting long-term survival in patients with NPC.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"162 ","pages":"Article 107187"},"PeriodicalIF":4.0,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143464185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}